Wedbush Brokers Decrease Earnings Estimates for Pharvaris

Pharvaris (NASDAQ:PHVS) – Investment analysts at Wedbush dropped their Q1 2025 earnings per share estimates for shares of Pharvaris in a report issued on Monday, April 7th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.92) for the quarter, down from their previous estimate of ($0.77). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Pharvaris’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.70) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($2.46) EPS and FY2028 earnings at $0.43 EPS.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Monday, April 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.06.

Separately, JMP Securities raised their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Up 0.8 %

Shares of Pharvaris stock opened at $12.00 on Thursday. The company has a market cap of $627.48 million, a P/E ratio of -4.29 and a beta of -2.84. The firm’s 50 day moving average price is $15.55 and its 200-day moving average price is $18.36. Pharvaris has a 52-week low of $11.51 and a 52-week high of $25.50.

Hedge Funds Weigh In On Pharvaris

Hedge funds have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pharvaris in the 3rd quarter worth approximately $906,000. State Street Corp purchased a new position in shares of Pharvaris in the third quarter worth $1,000,000. Jane Street Group LLC acquired a new stake in shares of Pharvaris during the third quarter worth $526,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris during the third quarter valued at $57,000. Finally, Barclays PLC acquired a new position in shares of Pharvaris in the 3rd quarter valued at $106,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.